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ucleus.Abstract A series of Ethyl 2-[2-(2,5-disubstituted-1H-indol-3-yl)-4-oxothiazolid-3-ylamino]-5,6-
dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carboxylates (4a–g) were synthesized from cyclocondensa-
tion of Ethyl 2-{(2E)-2-[(2,5-disubstituted-1H-indol-3-yl) methy leno] hydrazine}-5-oxo-5,6-dihy-
dro-4H-1,3,4-thiadiazine-6-carboxylates (3a–g) with thioglycolic acid in the presence of the
catalytic amount of zinc chloride. The compounds 3a–g were obtained from the reaction of Ethyl
2-hydrazinyl-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carboxylate (2) with various substituted
indole-3-carboxaldehydes 1a–g. Newly synthesized compounds were characterized by using IR,
1H NMR, Mass spectral and analytical data. Title compounds were evaluated for their in vitro anti-
microbial activities against various microbial strains and selected compounds were tested for their
analgesic and anti-inﬂammatory activities. Some of the newly synthesized Indolyl 4-thiazolidinone
analogues displayed signiﬁcant activity towards antimicrobial, analgesic and anti-inﬂammatory
activities.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Indole and its derivatives occupied a unique place in the chem-
istry of nitrogen heterocyclic compounds because of their var-
ied biodynamic properties (Biradar et al., 2010; Mohit et al.,
2007; Sharma et al., 2010) and thiadiazine derivatives are also
reported to possess diverse biological activities (Jaishree et al.,
2009; Prakash et al., 2008; Shivarama et al., 2002). In addition,302 12658.
(D.P. Anekal).
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biological activity and broad-spectrum action of their deriva-
tives (Verma and shailendra, 2008), such as bactericidal
(Kouatli et al., 2010), fungicidal (Anshu et al., 2006), anti-con-
vulsant (Dimri and Parmar,1978), anti-inﬂammatory (Bhawna
et al., 1999), anaesthetic (Manrao and Kohli, 1986), potentia-
tion of phenobarbital induced sleeping time (Manrao et al.,
1982) and potent Anti-HIV agents (Maria et al., 2002). Based
on these facts and in continuation of our research on the syn-
thesis of bioactive Indole analogues (Biradar and Doddappa,
2007; Doddappa and Biradar, 2009) and interest in thiazolidi-
nones (Renuka and Biradar, 2000) as a bioactive active entity,
we designed to synthesize novel Indolyl 4-thiazolidinone deriv-
atives as triheterocycles containing the bioactive heterocyclic
ring with the expectation of enhanced biological activity of
the molecule. Hence we have synthesized substituted Indolyling Saud University.
thesis and biological evaluation of novel Indolyl 4-thiazolidi-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.041
2 D.P. Anekal, J.S. Biradar4-thiazolidinones bearing the thiadiazine ring, and carried out
antimicrobial assay against various bacterial and fungal micro-
organisms. Selected compounds were evaluated for analgesic
and anti-inﬂammatory activities.
2. Experimental
2.1. General procedure
Melting points were determined in open capillaries and were
uncorrected. IR spectra were recorded in KBr on a Perkin-El-
mer Spectrum-one FTIR Spectrophotometer (m max in cm1)
and 1H NMR spectra on a DSX 300 MHz FTNMR Spectrom-
eter (Chemical shift in d ppm down ﬁeld from TMS as an inter-
nal reference). The Mass spectra were recorded on MS-Trap-
SL instruments.
2.2. General procedure for Ethyl 2-{(2E)-2-[(2,5-disubstituted-
1H-indol-3-yl)methyleno] hydrazine}-5-oxo-5,6-dihydro-4H-
1,3,4-thiadiazine-6carboxylate (3a–g)
Ethyl 2-hydrazinyl-5, 6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-
carboxylate (2) (2.1 g, 0.01 m) and 2,5-disubstituted-1H-in-
dol-3-carboxaldehydes(1a–d) (0.01 m) and fused sodium
acetate (0. 82 g, 0.01 m) were heated at reﬂux in ethyl alcohol
(20 mL) for six hrs. The solution was then concentrated
under vacuum and poured over crushed ice to get ethyl 2-
{(2E)-2-[(-[(5, 2-disubstituted -1H-indol-3-yl) methyleno]
hydrazine}-5-oxo-5,6-dihydro-4H-1,3,4-thiadiazine-6-carboxyl-
ate (3a–g). The analytical and spectral data of these com-
pounds are given as follows.
2.2.1. Ethyl2-{(2E)-2-[(5-chloro-2-phenyl-1H-indol-3-yl)meth-
yleno]hydrazine}-5-oxo-5,6-dihydro-4H-1,3,4-thiadiazine-6-
carboxylate(3a)
Pale yellow crystals, Yield 80%, m.p. 249–251 C. IR(KBr): 3162
(NH), 3000/2855 (NH/NH), 1743 (C‚O), 1631 (C‚O), 1456
(C‚N), 1H NMR in d (CDCl3): 2.4 (t, 3H, CH3), 3.3 (q, 2H,
CH2), 4.3 (s, 1H, S-CH), 7.1-8.1 (m, 8H, ArH), 8.9 (s, 1H, N–
NH), 12.3 (s, 1H, CO-NH), 10.0 (s, 1H, IndoleNH), 6.4 (s, 1H,
CH‚N); LC-MS(m/z): 267(7%) & 269(2%), 236(100%) &
238(32%), 214(6%) &216(1.5%); Anal. Calcd. For C21H18
ClN5O3S.C55.32,H3.98,N15.36. FoundC55.30,H,3.94,N15.32.
2.2.2. Ethyl 2-{(2E)-2-[(5-bromo-2-phenyl-1H-indol-3-yl)meth-
yleno]hydrazine}-5-oxo-5,6-dihydr o-4H-1,3,4-thiadiazine-6-
carboxylate (3b)
yellow crystals, Yield 72%, m.p. 244-246 C. IR(KBr): 3312
(NH), 298/2868 (NH/NH), 1723 (C‚O), 1654 (C‚O), 1486
(C‚N); 1H NMR in d: 2.1 (t, 3H, CH3), 3.6 (q, 2H, CH2),
4.0 (s, 1H, S-CH), 7.4-8.1 (m, 8H, ArH), 8.3 (s, 1H, N-NH),
11.7 (s, 1H, CO-NH), 9.8 (s, 1H, IndoleNH), 6.2 (s, 1H,
CH‚N); Anal. Calcd. for C21H18N5O3SBr. C50.41, H3.63,
N14.0. Found C50.39, H3.61, N14.01.
2.2.3. Ethyl 2-{(2E)-2-[(5-methyl-2-phenyl-1H-indol-3-yl)meth-
yleno]hydrazine}-5-oxo-5,6-dihydr o-4H-1,3,4-thiadiazine-6-
carboxylate (3c)
Yellow amorphous solid, Yield 65%, m.p. 244–246 C.
IR(KBr): 3159 (NH), 2920/2800 (NH/NH), 1729 (C‚O),
1656 (C‚O), 1454 (C‚N); 1H NMR in d: 1.8 (t, 3H, CH3),Please cite this article in press as: Anekal, D.P., Biradar, J.S. Syn
nones bearing thiadiazine nucleus. Arabian Journal of Chemistry3.6 (q, 2H, CH2), 2.4 (s, 3H, Ar–CH3), 4.2 (s, 1H, S–CH),
6.9–7.8 (m, 8H, ArH), 6.8 (s, 1H, N–NH), 11.2 (s, 1H, CO–
NH), 9.5 (s, 1H, IndoleNH), 6.0 (s, 1H, CH‚N); Anal. Calcd.
for C22H21N5O3S. C60.67, H4.86, N16.08. Found C60.65,
H4.84, N16.06.
2.2.4. Ethyl 2-{(2E)-2-[(5-methoxy-2-phenyl-1H-indol-3-yl)meth-
yleno]hydrazine}-5-oxo-5,6-dihy dro-4H-1,3,4-thiadiazine-6-
carboxylate (3d)
light yellow amorphous, Yield 70%, m.p. 244–246 C.
IR(KBr): 2934 (NH), 2840/2843 (NH/NH), 1750 (C‚O),
1612 (C‚O), 695 (–S–); 1H NMR in d: 2.1 (t,3H,CH3), 4.6
(q,2H,CH2), 3.2 (s,3H,O–CH3), 4.3 (s,1H,S–CH), 6.8–7.8
(m,8H,ArH), 6.6 (s,1H,N-NH), 11.6 (s,1H,CO–NH), 10.2
(s,1H, IndoleNH), 6.2 (s, 1H, CH‚N); Anal. Calcd. for
C22H21N5O4S. C58.52, H4.69, N15.51. Found C58.50,
H4.66, N15.49.
2.2.5. Ethyl 2-{(2E)-2-[(2-phenyl-1H-indol-3-yl) methyleno]
hydrazine}-5-oxo-5,6-dihydro-4H-1, 3,4-thiadiazine-6-carbox-
ylate (3e)
Grey crystals, Yield 70%, m.p.274–276 C. IR(KBr): 3064
(NH), 2978/2868 (NH/NH), 1743 (C‚O), 1634 (C‚O),
1487 (C‚N); 1H NMR in d: 2.2 (t, 3H, CH3), 3.8 (q, 2H,
CH2), 4.2 (s, 1H, S–CH), 6.9-7.7 (m, 9H, ArH), 6.8 (s, 1H,
N–NH), 11.4 (s, 1H, CO–NH), 8.9 (s, 1H, IndoleNH), 7.8 (s,
1H, CH‚N); Anal.Calcd.for C21H19N5O3S. C59.84, H4.54,
N16.62. Found C59.83, H4.51, N16.60.
2.2.6. Ethyl 2-{(2E)-2-[(2-methyl-1H-indol-3-yl) methyleno]
hydrazine}-5-oxo-5, 6-dihydro-4H-1, 3, 4-thiadiazine-6-carbox-
ylate (3f)
light yellow crystals, Yield 80%, m.p.184-186 C. IR(KBr):
3311(NH), 2983/2901 (NH/NH), 1757/1607 (C‚O/C‚O),
1583 (C‚N); 1H NMR in d: 2.0 (t, 3H, CH3), 2.3 (t, 3H,
Ar–CH3), 3.9 (q, 2H, CH2), 4.1 (s, 1H, S–CH),7.0–8.0 (m,
9H, ArH), 6.9 (s, 1H, N–NH), 12.4 (s, 1H, CO–NH), 9.2 (s,
1H, IndoleNH), 6.2 (s, 1H, CH‚N); Anal. Calcd. for
C16H17N5O3S. C53.47, H4.77, N19.49. Found C53.45,
H4.75, N,19.45.
2.2.7. Ethyl 2-{(2E)-2-[(1H-indol-3-yl)methyleno]hydrazine}-
5-oxo-5,6-dihydro-4H-1,3,4-thiadiaz ine-6-carboxylate (3g)
Grey crystals, Yield 75%, m.p.140–141 C. IR(KBr): 3315
(NH), 2979/2932 (NH/NH), 1743 (C‚O), 1607 (C‚O),
1440 (C‚N); 1H NMR in d:2.2 (t, 3H, CH3), 4.1 (q, 2H,
CH2), 4.1 (s, 1H, S–CH), 7.2–7.5 (m, 5H, ArH), 7.1 (s, 1H,
N–NH), 8.2 (s, 1H, CO–NH), 10.1 (s, 1H, IndoleNH), 7.4 (s,
1H, CH‚N); Anal. Calcd. for C15H15N5O3S. C52.16, H4.38,
N20.28. Found C52.13, H4.36, N20.25.
2.3. General procedure for Ethyl2-[2-(2,5-disubstituted-1H-indol-
3-yl)-4-oxothiazolid-3-ylamino]-5,6-dihydro-5-oxo-4H-1,34-thia-
diazine-6-carboxylate (4a–g)
A mixture of ethyl 2-{(2E)-2-[(-[(2,5-disubstituted -1H-indol-3-yl)
methyleno] hydrazine}-5-oxo-5, 6-dihydro-4H-1,3,4-thiadiazine-
6-carboxylates (0.01mole) (3a–g), thioglycolic acid (mercaptoace-
tic acid) (0.01 m) and catalytic amount of zinc chloride
(anhydrous) in dimethylformamide (25 mL) was heated at reﬂuxthesis and biological evaluation of novel Indolyl 4-thiazolidi-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.041
Synthesis and biological evaluation of novel Indolyl 4-thiazolidinones bearing thiadiazine nucleus 3for 6–8 h. The reaction mixture was cooled and poured into
crushed ice, thus the product obtained was ﬁltered, washed with
cold water and recrystallized from suitable solvent. The products
consequently obtained were characterized by spectroscopic and
analytical data as follows;
2.3.1. Ethyl 2-[2-(5-chloro-2-phenyl-1H-indol-3-yl)-4-oxothiaz-
olid-3-ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carb-
oxylate (4a)
Yellow crystals, Yield 77%, m.p. 264–266 C. IR(KBr): 3141
(NH), 3060/2853 (NH/NH), 1659/1628 (C‚O/C‚O), 1588
(C‚N), 799/762 (-S-/-S-); 1H NMR in d(CDCl3): 1.8 (t, 3H,
CH3), 4.2 (q, 2H,–CH2–), 3.6 (s, 1H, SCH), 3.8 (s, 1H, Ar-
CH), 4.8 (s,2H,S-CH2), 7.3-7.8 (m, 8H, ArH), 8.2 (s, 1H, N–
NH), 12.6 (s, 1H, CO–NH), 9.9 (s, 1H, indoleNH); MS(m/z):
(M+.) 527 (2%), (M + 2) 529 (0.5%), 452 (2%) & 454
(0.5%), 368 (8%) &370 (3%), 253 (100%) and m/z 255
(30%); Anal. Calcd. for C23H18N5O4S2Cl. C52.12, H3.80,
N13.2. Found C51.10, H3.78, N13.20.
2.3.2. Ethyl 2-[2-(5-bromo-2-phenyl-1H-indol-3-yl)-4-oxothiaz-
olid-3-ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carb-
oxylate (4b)
Light yellow crystals, Yield 65%, m.p.246–248 C. IR(KBr):
3110 (NH), 2971/2615 (NH/NH), 1761/1663 (C‚O/C‚O),
1580 (C‚N), 760/720 (-S-/-S-); 1H NMR in d: 2.0 (t, 3H,
CH3), 4.0 (q, 2H, CH2), 4.1 (s, 1H, SCH), 4.3 (s, 1H, Ar–
CH), 4.0 (s, 2H, S–CH2), 7.3-7.7 (m, 8H, ArH), 7.2 (s, 1H,
N–NH), 11.3 (s, 1H, CO–NH), 9.0 (s, 1H, indoleNH); Anal.
Calcd. for C23H20BrN5O4S2. C48.09, H3.51, N12.19. Found
C48.05, H3.49, N12.15.
2.3.3. Ethyl 2-[2-(5-methyl-2-phenyl-1H-indol-3-yl)-4-oxothiaz-
olid-3-ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carbo-
xylate (4c)
Yellow amorphous solid, Yield 70%, m.p.176–178 C.
IR(KBr): 3262 (NH), 2910/2750 (NH/NH), 1716 (C‚O),
1630/1620 (C‚O/C‚O), 1483 (C‚N), 764 (-S-); 1H NMR
in d: 1.8 (t, 3H, CH3), 2.6 (s, 3H, Ar–CH3), 4.2 (q, 2H, CH2),
4.0 (s, 1H, SCH), 4.8 (s, 1H, Ar–CH), 4.2 (s, 2H, S–CH2),
7.3-7.5 (m, 8H, ArH), 7.1 (s, 1H, N–NH), 10.8 (s, 1H, CO–
NH), 9.8 (s, 1H, indoleNH); Anal. Calcd. for C24H23N5O4S2.
C56.57, H4.55, N13.74. Found C56.55, H4.52, N13.70.
2.3.4. Ethyl 2-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)-4-oxothia-
zolid-3-ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carb-
oxylate (4d)
Dark yellow crystals, Yield 55%, m.p.184–186 C. IR(KBr):
3046 (NH), 2934/2830 (NH/NH), 1809 (C‚O), 1656/1601
(C‚O/C‚O),755 (-S-); 1H NMR in d: 2.2 (t, 3H, CH3), 4.2
(q, 2H, CH2), 3.6 (s, 3H, Ar-CH3), 4.0 (s, 1H, SCH), 4.9 (s,
1H, Ar–CH), 3.8 (s, 2H, S–CH2), 6.9-7.5 (m, 8H, ArH), 6.8
(s, 1H, N–NH), 10.9 (s, 1H, CO–NH), 10.0 (s, 1H, indoleNH);
Anal. Calcd. for C24H23N5O5S2. C54.84, H4.41, N13.32.
Found C54.82, H4.37, N13.30.
2.3.5. Ethyl 2-[2-(2-phenyl-1H-indol-3-yl)-4-oxothiazolid-3-
ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carboxylate
(4e)
Yellow crystals, Yield 78%, m.p. 278–280 C. IR(KBr): 3252
(NH), 2900/2850 (NH/NH), 1711 (C‚O), 1660/ 1680Please cite this article in press as: Anekal, D.P., Biradar, J.S. Syn
nones bearing thiadiazine nucleus. Arabian Journal of Chemistry(C‚O/C‚O), 1487 (C‚N), 745 (-S-); 1H NMR in d: 2.3 (t,
3H, CH3), 3.2 (q, 2H, CH2), 4.0 (s, 1H, SCH), 5.1 (s, 1H,
Ar–CH), 4.3 (s, 2H, S–CH2), 7.0-7.5 (m, 9H, ArH), 6.8 (s,
1H, N–NH), 11.2 (s, 1H, CO–NH), 9.8 (s, 1H, indoleNH);
Anal. Calcd. for C23H21N5O4S2. C55.74, H4.27, N14.13.
Found C55.74, H4.26, N14.10.
2.3.6. Ethyl 2-[2-(2-methyl-1H-indol-3-yl)-4-oxothiazolid-3-
ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carboxylate
(4f)
Grey crystals, Yield 65%, m.p.308–310 C. IR(KBr): 2918
(NH), 2800/2780 (NH/NH), 1728 (C‚O), 1650 (C‚O), 746
(-S-); 1H NMR in d: 2.0 (t, 3H, CH3), 4.2 (q, 2H, CH2), 2.2
(s, 3H, CH3), 4.1 (s, 1H, SCH), 4.6 (s, 1H, Ar–CH), 3.8 (s,
2H, S–CH2),7.0-7.5 (m, 4H, ArH), 6.8 (s, 1H, N–NH), 12.2
(s, 1H, CO-NH), 10.2 (s, 1H, indoleNH); Anal. Calcd. for
C18H19N5O4S2. C49.87, H4.42, N16.16. Found C49.86,
H4.41, N16.14.
2.3.7. Ethyl2-[2-(1H-indol-3-yl)-4-oxothiazolid-3-ylamino]-
5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carboxylate (4g)
Dark yellow crystals, Yield 80%, m.p.238–240 C. IR (KBr):
3272 (NH), 3030/2910 (NH/NH), 1718(C‚O), 1606/
1580(C‚O/C‚O), 744 (-S-); 1H NMR in d: 1.4 (t, 3H,
CH3), 4.2 (q, 2H, CH2), 4.2 (s, 1H, SCH), 5.1 (s, 1H, Ar–
CH), 3.9 (s, 2H, S–CH2), 7.1-7.6 (m, 5H, ArH), 7.0 (s, 1H,
N–NH), 10.6 (s, 1H, CO–NH), 10.2 (s, 1H, indoleNH);
MS(m/z): (M+.) 419 (10%), 233 (50%), 185 (20%), 245
(60%), 176 (30%), 140 (100%), 90 (10%). Anal. Calcd. for
C17H17N5O4S2. C48.68, H4.08, N16.70. Found C48.42,
H4.02, N16.38.
3. Results and discussion
The requisite compound Ethyl 2-hydrazinyl-5,6-dihydro-5-oxo-
4H-1,3,4-thiadiazine-6-carboxylate (2) was prepared from the
literature method (Chande et al., 2000) and 2,5-disubstituted in-
dole-3-corboxaldehydes (1a–d)were prepared from the Bischler
method of Indole synthesis followed by Vilsmeier–Haack
formylation (Hiremath et al., 1982). Synthetic pathway for
Ethyl 2-{(2E)-2-[(2,5-disubstituted-1H-indol-3-yl) methyleno]
hydrazine}-5-oxo-5,6-dihydro-4H-1,3,4-thiadiazine-6carboxyl-
ates (3a–g) and Ethyl2-[2-(2,5-disubstituted-1H-indol-3-yl)-4-
oxothiazolid-3-ylamino]-5,6-dihydro-5-oxo-4H-1,3,4-thiadi-
azine-6-carboxylates (4a–g) is summarized in Scheme 1. An
equimolar mixture of substituted thiadiazine (2), substituted in-
dole-3-carboxaldehyde (1a–d) and sodium acetate were reﬂuxed
in ethanol (20 mL) for 6–7 h. The solution was then concen-
trated under reduced pressure up to half of the original volume
and poured over crushed ice; it was then ﬁltered, dried and
recrystallized from ethanol to obtain compound 3a–g. The for-
mation of compound 3a is conﬁrmed by their spectral and ana-
lytical data as follows: IR spectrum of compound 3a as an
example, showed the peak at 3162 cm1 due to indole NH
groups, 3000 cm1 and 2855 cm1due to secondary aliphatic
amine groups, carbonyls appeared at 1743 cm1 and
1631 cm1 for ester carbonyl and azine carbonyl. Other peaks
at 1456 cm1 and 767 cm1 are due to C‚N and –S–, respec-
tively. 1H NMR spectrum of compound 3a showed the peaks
at 3.3 d for –CH2– and 2.4 d –CH3 for the ethyl group and 4.3
d for thiadiazine S–CH single proton. A multiplet appearedthesis and biological evaluation of novel Indolyl 4-thiazolidi-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.041
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4 D.P. Anekal, J.S. Biradarbetween 7.1 and 8.1 d due to deshielded aromatic protons. Two
singlets are at 8.9 d and 12.3 d for N–NH and N–NH–CO of the
thiadiazine ring protons. Singlet at 10 d is due to the dishielded
indole NH. Peak at 6.4 d is due to the deshielded protons of
CH‚N. Mass spectrum of 3a has not shown the molecular
ion peak, it may be due to the unstability of the molecular ion.
Molecular ion has undergone into fragmentation displaying
the peaks A1 at m/z 267(7%) and m/z 269(2%). A1 has under-
gone into further fragmentation by two routes. In one route it
has lost N2 and H2 showed peaks A2 at m/z 236(100%) and
m/z 238(32%), in another route it has lost CN andN2 to display
peaks A3 at m/z 214(6%) and m/z 216(1.5%). A3 has then lost
the chlorine radical and displayed peak A4 at 178(7%). Frag-
ment A4 loses C2H2 to displayed peak A5 at m/z 154(98%). This
fragmentation pattern of the mass spectrum supports the pro-
posed structure of compound 3a. (See Schemes 2 and 3)
The ﬁnal compounds 4a–g were synthesized by equimolar
ratio of the compound 3a–g and thiaglycolic acid (mercapto
acetic acid) in dimethylformamide with catalytic amount of
zinc chloride (anhydrous), then the reaction mixture was re-
ﬂuxed for 6–8 h. The reaction mixture was cooled and poured
into crushed ice, the product thus obtained was ﬁltered,
washed with cold water and recrystallized from ethanol/1, 4-
diaxane to afford compound 4a–g. The formation of the title
compounds conﬁrmed by their spectral and analytical reports
are as follows; IR spectrum of compound 4a as an example,
showed characteristic peaks at 3141 cm–1 and 3060 cm–1 for in-
dole and thiadiazine NH, respectively. The peaks at
1659 cm1, 1628 cm1 are due to two carbonyls. Appearance
of two peaks at 799 cm1 and 762 cm1 are for the thio(-S-)
group of thiadiazine and cyclized thiozolidinone ring, respec-
tively. 1H NMR spectrum of compound 4a showed peaks at
1.8 d (t, 3H, CH3) and 4.2 d (q, 2H, CH2) are for the ethyl at-
tached to the thiadiazine ring. Singlets appearing at 3.6 d (S–
CH) and 12.6 d (CO–NH) are the protons of the thiadiazine
ring. A characteristic peak at 4.8 d (s, 2H, thiazolidinone) is
due to the two protons of the thiazolidinone methylene group.
Singlet appearing at 3.4 d is accounted for a proton of the thia-
zolidinone ring (–CH‚). Multiplet in the region 7.3–7.8 d (m,
8H, ArH) is due to the aromatic protons. Deshielded indole –
NH– appeared at 9.9 d. Structure of compound 4a is further
supported by the mass spectrum.
Mass spectrum of compound 4a has shown the molecular
ion peak M+ at m/z 527(2%) and m/z 529(0.5%), which isPlease cite this article in press as: Anekal, D.P., Biradar, J.S. Syn
nones bearing thiadiazine nucleus. Arabian Journal of Chemistryin agreement with the molecular weight of the compound.
Molecular ion peak had undergone further fragmentation
and displayed the peaks A1 at m/z 452(2%) and m/z
454(0.5%), A2 at m/z 368(8%) and m/z 370(3%). Anotherthesis and biological evaluation of novel Indolyl 4-thiazolidi-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.041
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Scheme 3 Mass fragmentation of compound 4a.
Synthesis and biological evaluation of novel Indolyl 4-thiazolidinones bearing thiadiazine nucleus 5fragment A3 is at m/z 326(10%) and m/z 328(3%). A3 elimi-
nates C2H4OS and displayed stable fragment A4 at m/z
253(100%) and m/z 255(30%), A4 then lost CN, Cl and
C2H2N to generate A5 at m/z 152 (1%). This fragmentation
pattern of the mass spectrum supports the proposed structure
of compound 4a. Structures of other derivatives of the series
(3b–g) and (4b–g) were conﬁrmed based on their spectral and
analytical data. C,H,N elemental analysis for the title com-
pounds 3a–g and 4a–g indicated that the calculated and ob-
served values were within acceptable limits (±0.4%).
3.1. Antimicrobial activity
Title compounds were screened for in-vitro antimicrobial activ-
ities using the cup plate diffusion method (Indian Pharmaco-
poeia, Controller of Publication, Delhi, India. 1996) and
antibacterial species used are two Gram negative species Esch-
erichia coli, Pseudomonas aeruginosa and two Gram positive
species Bacillus subtilis, Staphylococcus aureus. Four fungal
strains Aspergillus niger, Penicillium chrysogenum, Aspergillus
ﬂavus, Aspergillus fumigatus are used for antifungal activity.
Solution of each compound at a concentration of 100 lg/
0.1 mL in DMF was prepared and the inhibition zone diameter
in centimetre (IZD) was used as the criterion for measuring the
microbial activity. Gentamycin, Ciproﬂoxacin were used as
bacterial standards and Fluconazole, Greseofulvin were used
as fungal standards for references to evaluate the efﬁcacy ofPlease cite this article in press as: Anekal, D.P., Biradar, J.S. Syn
nones bearing thiadiazine nucleus. Arabian Journal of Chemistrythe tested compounds under the same conditions. Dimethyl
formamide was used as control and solvent to prepare com-
pound solutions as 10 mg per 10 mL. The results are depicted
in Table 1. Compounds 3e, 3g, 4a and 4d exhibited relatively
signiﬁcant activity against E. coli, 4c and 4g against S. aureus
and 3g with B. subtilis. Other compounds 3a, 3c, 3d, 4e and 4f
showed moderate activity. In antifungal activities compound
3g displayed highest activity against A. niger, 4d against A. ﬂa-
vus, 3d and 3f against A. fumigatus micro-organisms. 3a, 3d
and 3e compounds have shown moderately active. Remaining
compounds in antimicrobial screening exhibited weekly to
inactive bioavailability. Most of the compounds containing al-
kyl or alkoxy and phenyl substitution at position 5 and 2 of the
indole moiety exhibited more actively than the other com-
pounds of the series.
3.2. Analgesic and anti-inﬂammatory activities
Selected compounds bearing pharmacophores were evaluated
for the analgesic and anti-inﬂammatory activities using Wister
mice and albino rats according to literature procedures (Kulk-
arni, 1980; Damour and Smith, 1941; Winter et al., 1962).
Analgesic activity was performed by the tail-ﬂick method
using analgesiometer, newly synthesized compounds were
administered orally at a dose level of 100 mg/kg body weight
of the Wister albino mice of either sex excluding pregnant mice
weighing 25–30 g by the random sampling technique. The drugthesis and biological evaluation of novel Indolyl 4-thiazolidi-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.041
Table 1 In vitro antimicrobial assay of newly synthesized 3a–g and 4a–g compounds.
Comp’s. (R,R1) Zone of inhibition in mm
Antibacterial activity Antifungal activity
E. coli P. aeruginosa S. aureus B. subtilis A. niger P. chrysogenium A. ﬂavus A. fumigatus
3a (Cl,Ph) 17 12 17 14 14 14 14 12
3b (Br,Ph) 13 15 16 11 10 11 14 12
3c (Me,Ph) 17 12 16 24 15 14 13 16
3d (OMe,Ph) 17 12 13 18 17 10 15 10
3e (H,Ph) 19 15 14 18 14 16 11 14
3f (H,Me) 15 12 12 15 11 12 11 16
3g (H,H) 21 13 14 22 20 10 14 10
4a (Cl,Ph) 18 16 12 17 16 10 12 10
4b (Br,Ph) 15 15 13 08 10 12 11 14
4c (Me,Ph) 08 12 24 18 14 12 15 13
4d (OMe,Ph) 18 15 18 13 14 15 18 10
4e (H,Ph) 17 14 12 19 14 14 11 12
4f (H,Me) 16 12 18 14 12 10 13 10
4g (H,H) 16 13 22 21 15 10 15 10
Gentamicin 18 18 21 23 – – – –
Ciproﬂoxacin 19 20 19 24 – – – –
Fluconazole – – – – 18 15 23 18
Greseofulvin – – – – 20 18 18 16
DMF(Control) 08 08 08 08 08 08 08 08
Key for interpretation: Inactive: <12 mm, weakly active: 12–14 mm, moderately active: 15–17 mm, highly active: more than 17 mm
Table 1 Analgesic activity results of some synthesized compounds.
Compd. No. Substituents Dose (mg/kg) Average (±SE) reaction time (sec) Time after drug treatment (min) Percent analgesia (%)
0 min 30 min 60 min 90 min 30 min 90 minR R1
Control – – – 4.10 (±0.241) 3.91 (±0.310) 3.10 (±0.010) 3.72 (±0.318) – –
Analgin – – 100 3.21** (±0.025) 6.71** (±0.32) 10.5** (±0.41) 10.9** (±0.32) 39.49 98.62
3a Cl Ph 100 3.75 (±0.41) 4.11 (±0.43) 6.1** (±0.48) 6.6** (±0.34) 2.82 39.56
3b Br Ph 100 3.9 (±0.217) 4.2 (±0.13) 4.9* (±0.25) 5.2* (±0.211) 4.09 20.32
3c CH3 Ph 100 3.91 (±0.235) 4.23 (±0.00) 5.9
** (±0.100) 5.4** (±0.22) 4.51 23.01
4a Cl Ph 100 4.41 (±0.23) 4.25 (±0.28) 5.10** (±0.08) 5.51** (±0.39) 4.79 24.58
4b Br Ph 100 4.21 (±0.266) 4.70 (±0.171) 5.30** (±0.281) 5.0* (±0.00) 11.14 17.58
4c CH3 Ph 100 4.01 (±0.28) 5.21
* (±0.31) 9.21** (±0.03) 10.23** (±0.09) 18.33 89.42
4d OCH3 Ph 100 4.71
** (±0.47) 8.71** (±0.40) 10.49** (±0.48) 10.82** (±0.43) 67.70 97.52
4e H Ph 100 3.70 (±0.431) 5.2* (±0.09) 5.63* (±0.25) 6.00** (±0.08) 18.19 31.31
4f H CH3 100 3.75 (±0.31) 6.25
** (±0.25) 10.24** (±0.48) 10.78** (±0.38) 33.00 96.9
Signiﬁcance levels *P< 0.05, **P< 0.01 compared with respective control (ANOVA followed by Dunnett’s test). Each value represents ±SE
(n= 6).
* P< 0.05.
** P< 0.01.
6 D.P. Anekal, J.S. BiradarAnalgin was administered as a reference standard at a dose le-
vel 100 mg/kg for comparison for the test compounds in same
concentration. The reaction time was recorded at 0, 30, 60 and
90 min, cut off time was 10 sec. The percent analgesia was cal-
culated and tabulated in Table 2.
In antiinﬂammatory activities, synthesized new compounds
were administered orally at a dose level of 100 mg/kg body
weight of the albino rats of both sexes excluding pregnant rats
weighing 170–240 g. The paw volume was measured using the
mercury displacement technique with the help of plethysmo-
graph immediately before and 2 h and 4 h after carrageenan
(1%, 0.1 ml) injection. The percent inhibition of oedema was
calculated and indomethacin was used as reference standard
(Table 3).Please cite this article in press as: Anekal, D.P., Biradar, J.S. Syn
nones bearing thiadiazine nucleus. Arabian Journal of ChemistryTable 2 reports the analgesic activity results obtained from
novel Indolyl 4-thiazolidinones. Compounds 4c, 4d and 4f dis-
played percent analgesia signiﬁcantly as 89.42%, 97.52% and
96.9%, respectively. It has been found that compounds with
substitutions as –OCH3, –CH3, –H at position 5 and –Ph, –
CH3 at position 2 of Indole moiety in the cyclized thiazolidi-
none ring are more active analgesics than other analogues. It
has been observed from Table No. 3, Indolyl thiazolidinone
analogues have shown good anti-inﬂammatory activity. Here
4a with inhibition 40.67%, 4b with 50.42%, 4d with 55.08%,
4e with 42.37% and 4f with 55.50% were obtained at 4 h.
The compound substitutions in position 5 and 2 of the indole
moiety were found to be more active than other molecules.
Remaining compounds of the series have shown moderate tothesis and biological evaluation of novel Indolyl 4-thiazolidi-
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.041
Table 2 Anti-inﬂammatory results of some synthesized compounds.
Compd. No. Substituents Dose (mg/kg) Mean values (±SE) of oedema
volume at diﬀerent intervals
Percentage inhibition of
inﬂammation at diﬀerent intervals (%)
R R1 2 h 4 h 2 h 4 h
Control – – – 0.239 (0.0113) 0.236 (0.018) – –
Standard – – 100 0.176* (±0.020) 0.101** (±0.000) 26.4 57.2
3a Cl Ph 100 0.224 (±0.006) 0.177 (±0.003) 6.3 25.0
3b Br Ph 100 0.222 (±0.006) 0.162 (±0.003) 7.11 31.35
3c CH3 Ph 100 0.220 (±0.015) 0.145
* (±0.04) 7.94 38.5
4a Cl Ph 100 0.222 (±0.016) 0.140** (±0.022) 7.11 40.67
4b Br Ph 100 0.208 (±0.000) 0.117** (±0.025) 12.97 50.42
4c CH3 Ph 100 0.243 (±0.020) 0.175 (±0.021) 1.67 25.84
4d OCH3 Ph 100 0.195 (±0.015) 0.106
** (±0.002) 18.41 55.08
4e H Ph 100 0.215 (±0.010) 0.136** (±0.021) 10.04 42.37
4f H CH3 100 0.194 (±0.017) 0.105
** (±0.002) 18.83 55.50
Signiﬁcance levels *P< 0.05, **P< 0.01compared with respective control (ANOVA followed by Dunnett’s test). Each value represents ±SE
(n= 6).
* P< 0.05.
** P< 0.01.
Synthesis and biological evaluation of novel Indolyl 4-thiazolidinones bearing thiadiazine nucleus 7weak activity in both analgesic and anti-inﬂammatory activi-
ties. An important observation we have made is that, experi-
mental animals have neither died nor shown any symptoms
of illness in our 24 h observation.4. Conclusion
We have synthesized series of novel Ethyl 2-{(2E)-2-[(2,5-disub-
stituted-1H-indol-3-yl) methy leno] hydrazine}-5-oxo-5,6-dihy-
dro-4H-1,3,4-thiadiazine-6carboxylates (3a–g) and Ethyl 2-[2-
(2,5-disubstituted-1H-indol-3-yl)-4-oxothiazolid-3-ylamino]-
5,6-dihydro-5-oxo-4H-1,3,4-thiadiazine-6-carboxylates (4a–g)
derivatives and screened them for in-vitro antimicrobial activi-
ties against various microbial strains. We found evidently that
compounds 3e, 3g, 4a, 4d, 4c, 4g and 3g, 4d, 3c, 3f are signiﬁ-
cantly active towards microbial organisms. Selected com-
pounds on the basis of SAR studies have been evaluated for
analgesic and anti-inﬂammatory activities. Among the title
compounds 4c, 4d and 4f have shown analgesic and 4a, 4b,
4d, 4e and 4f have displayed signiﬁcant anti-inﬂammatory
activities. The bioactivity of these compounds was unknown
and these studies may promote a further development of the
Indolyl 4-thiazolidinones, which may lead to compounds with
better pharmacological proﬁle than standard drugs.Acknowledgments
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